Adenylate cyclase (EC 4.6 Many antipsychotic drugs produce an extrapyramidal syndrome indistinguishable from Parkinson's disease (1, 2). There is considerable evidence that suggests that these extrapyramidal side effects may arise from the demonstrated ability of these drugs to antagonize the "dopamine receptor" of the caudate nucleus (3, 4), which many investigators have indirectly characterized in an extensive series of physiological, biochemical, and behavioral studies. Recently, a dopaminesensitive adenylate cyclase was demonstrated in homogenates of the caudate nucleus of the rat brain (5). It was suggested (5) that an intimate association exists between this dopaminesensitive adenylate cyclase and the "dopamine receptor" of the caudate nucleus, since the biochemical and pharmacological properties of this enzyme were similar to the reported properties of the caudate "dopamine receptor." A variety of evidence suggests that dopamine may serve as a neurotransmitter in several other regions of the mammalian nervous system, in addition to the caudate nucleus. Both the nucleus accumbens and the olfactory tubercle, two anatomical structures associated with the limbic system, are among the regions recently identified (6) as receiving dopaminergic innervation. Furthermore, biochemical measurements have shown the occurrence of relatively high levels of dopamine and 1113 its metabolites in these regions (refs. 7 and 8; 0. Hornykiewicz, personal communication; A. Carlsson, personal communication).
Many antipsychotic drugs produce an extrapyramidal syndrome indistinguishable from Parkinson's disease (1, 2) . There is considerable evidence that suggests that these extrapyramidal side effects may arise from the demonstrated ability of these drugs to antagonize the "dopamine receptor" of the caudate nucleus (3, 4) , which many investigators have indirectly characterized in an extensive series of physiological, biochemical, and behavioral studies. Recently, a dopaminesensitive adenylate cyclase was demonstrated in homogenates of the caudate nucleus of the rat brain (5) . It was suggested (5) that an intimate association exists between this dopaminesensitive adenylate cyclase and the "dopamine receptor" of the caudate nucleus, since the biochemical and pharmacological properties of this enzyme were similar to the reported properties of the caudate "dopamine receptor."
A variety of evidence suggests that dopamine may serve as a neurotransmitter in several other regions of the mammalian nervous system, in addition to the caudate nucleus. Both the nucleus accumbens and the olfactory tubercle, two anatomical structures associated with the limbic system, are among the regions recently identified (6) The evidence that the extrapyramidal syndrome produced by the antipsychotic drugs is attributable to the ability of these drugs to block caudate dopamine receptors, together with the evidence that dopamine occurs in several other re- gions of the nervous system, has focused attention (e.g., refs. 9-11) on the twin hypotheses (a) that the antipsychotic drugs may achieve their therapeutic effects by virtue of blocking dopamine receptors in the brain and (b) that a hyperactivity of dopaminergic pathways in the brain may be involved in the pathophysiology of schizophrenia. The mesolimbic dopaminergic system of the brain, which projects to the olfactory tubercle and the nucleus accumbens, has figured prominently in such speculations concerning the pathophysiology of schizophrenia and the site of action of the antipsychotic drugs (11) .
The results presented in this communication are consistent with a model in which the dopamine receptor of neural tissue is intimately associated with a dopamine-sensitive adenylate cyclase. The results are also compatible with the possibility that inhibition of this enzyme may provide an explanation, at the molecular level, for the therapeutic effects, as well as for the side effects, of some widely used antipsychotic agents.
MATERIALS AND METHODS
ATP, cyclic AMP, l-norepinephrine, and EGTA were purchased from Sigma; 3-hydroxytyramine (dopamine) was from CalBiochem^; inorganic salts were all reagent grade. All phenothiazines and related compounds were obtained, in high purity, from their commercial distributor.
The procedure for the dissection of the rat caudate nucleus [the nucleus caudate-putamen (12) ] has been described (5).
Caudate nuclei from other species were dissected in a manner similar to that used for the rat. The olfactory tubercle of the rat was removed from the ventral surface of the brain: a horizontal, medio-lateral cut was made up to the ventral surface of the anterior commissure; the lateral boundary was set by the olfactory tract. To dissect the nucleus accumbens of the guinea pig brain (13) , the olfactory tubercles were removed, the brain was bisected along the midline, the lateral ventricle of each hemisphere was opened, and the nucleus accumbens was exposed and separated from the extreme rostral end of the head of the caudate nucleus.
5-10 gM dopamine. In contrast, the fl-adrenergic agonist 1-isoproterenol had no significant effect on adenylate cyclase activity at concentrations as high as 1000l M. The catecholamine, l-norepinephrine, stimulated the adenylate cyclase activity of the olfactory tubercle to the same maximal level as did dopamine (data not shown); however, considerably greater concentrations of l-norepinephrine than of dopamine were required to achieve a given increase in enzyme activity (e.g., 30 /AM l-norepinephrine was required for half-maximal stimulation, and 300 MM, or greater, for maximal stimulation). The increase in enzyme activity in the presence of a combination of dopamine and l-norepinephrine, each at a maximally stimulating concentration, was no greater than with either agent alone; this nonadditivity suggests that l-norepinephrine interacts with the same receptor as does dopamine. Thus, the sensitivity of the adenylate cyclase of the olfactory tubercle to these several catecholamines was similar to that of the adenylate cyclase of the caudate nucleus, described earlier (5) .
Fluphenazine, one of the most potent phenothiazine compounds both as an antipsychotic agent as well as in producing extrapyramidal side effects in patients, was investigated for its effect upon the dopamine-sensitive adenylate cyclase activity of the olfactory tubercle (Fig. 2) Tissues were pooled and were homogenized in 50 volumes (weight to volume) of 2 mM tris-(hydroxymethyl)aminomethane-maleate buffer (pH 7.4)-2 mM EGTA. The standard assay system (final volume 0.5 ml) for measurement of adenylate cyclase [EC 4.6.1.1; ATP pyrophosphate-lyase (cyclizing) ] activity of homogenates contained (in mmol/liter): tris(hydroxymethyl)aminomethane-maleate, 80.2; ATP, 1.5; MgS04, 6.0; theophylline, 10; EGTA, 0.6 (including the amount introduced with the tissue homogenate); 0.05 ml of tissue homogenate; plus test substances as indicated. Incubation was for 2.5 min at 3Q0. The reaction was terminated, and cyclic AMP measured, as described (5). Data represent total cyclic AMP formation per assay tube. Under the experimental conditions used, enzyme activity was proportional to time and enzyme concentration. The concentrations of ATP (1.5 mM) and MgSO4(6.0 mM) utilized were in a range such that enzyme activity was independent of the concentration of these sub-
stances. RESULTS
The effect of various concentrations of the catecholamines, dopamine and l-isoproterenol, on the adenylate cyclase activity of a homogenate of the olfactory tubercle of the rat is shown in Fig. 1 Since the nucleus accumbens is smaller and less well defined, anatomically, than are either the olfactory tubercle or the caudate nucleus, it was felt preferable to isolate this nucleus from the guinea pig brain, which is considerably larger than the rat brain. The effect of 40 IM dopamine was tested on the adenylate cyclase activity of a preparation of nucleus accumbens both in the presence and in the absence of 0.5,gM fluphenazine (Table 1) . Low concentrations of dopamine were able to stimulate the adenylate cyclase activity of the nucleus accumbens homogenate; the stimulation by dopamine, representing approximately a 50% increase above basal activity, was less than the increase observed in either the olfactory tubercle or the caudate nucleus. This smaller stimulation of the enzyme from the nucleus accumbens may conceivably have resulted from contamination of this preparation by tissue from other (nondopaminergic) regions of the brain. Nonetheless, the increase above basal activity, seen in the presence of dopamine, was highly significant (i.e., P < 0.001). Fluphenazine, 0.5,M, abolished the stimulation of the nucleus accumbens enzyme by 40 MM dopamine, whereas this concentration of fluphenazine did not affect the basal enzyme activity.
With homogenates of the rat caudate nucleus, a half-maximal increase in enzyme activity was achieved, in various experiments, with 3.5-10 MM dopamine. The effect of fluphenazine was also studied on the dopamine-sensitive adenylate cyclase activity of the caudate nucleus (Fig. 3) . Fluphenazine competitively antagonized the stimulatory effect of dopamine on the adenylate cyclase of the caudate nucleus. The calculated inhibition constant (Ki) of fluphenazine for the caudate enzyme was 0.008 MuM. The potent and competitive nature of the action of fluphenazine as a dopamine antagonist on the caudate adenylate cyclase was similar to its action on the olfactory tubercle enzyme. In experiments similar to those illustrated for fluphenazine in Figs. 2 and 3 , it was found that three other phenothiazines (trifluoperazine, thioridazine, and chlorpromazine), a butyrophenone (haloperidol), and a dibenzodiazepine (clozapine), also inhibited the stimulation by dopamine of adenylate cyclase activity in homogenates from the caudate nucleus and from the olfactory tubercle of the rat. The inhibition followed competitive kinetics in all cases. The magnitude of the shift in the dose-response curve for dopamine, and the Ki calculated from this shift are tabulated in Table 2A for all six antipsychotic agents tested in this manner.
Many substances were also tested, over a range of concentrations, for their ability to inhibit the stimulation, by a constant amount of dopamine, of the adenylate cyclase activity in homogenates of the caudate nucleus and olfactory tubercle. Data obtained in this type of experiment are illustrated in Fig. 4 for fluphenazine, chlorpromazine, imipramine, and diethazine. The Lo for each compound tested in this manner, together with the KJ value calculated from the I5o on the basis of competitive kinetics, are tabulated in Table 2B . In those in- stances where a given substance was tested in both types of kinetic study, the Ki value was in fairly good agreement. Moreover, for each of several substances tested, the Ki value for the enzyme from the olfactory tubercle was similar to that for the enzyme from the caudate nucleus, even though the various compounds tested varied greatly in their potency.
There was greater than a 1000-fold range in the potency of the phenothiazines as antagonists of the stimulation by dopamine of-caudate adenylate cyclase activity. Interestingly, fluphenazine and trifluoperazine, which are especially potent clinically both as antipsychotic agents and in causing extrapyramidal side effects, had very low Ki values. Conversely, promethazine, imipramine, desmethylimipramine, ethoproperazine, and diethazine, which have little or no antipsychotic or extrapyramidal actions clinically, had relatively high Ki values, even though these compounds are closely related structurally to the psychoactive phenothiazines. Not surprisingly, there are a few discrepancies between the results of various test substances observed in our enzyme system with results of clinical trials and laboratory studies in vivo. For instance, thioridazine (14) , and especially clozapine (15) , at therapeutically effective levels, are reputed to have a low incidence of extrapyramidal side effects. Nevertheless, these substances were approximately as potent on the enzyme from the caudate nucleus as they were on the olfactory tubercle enzyme. Our results suggest that the low incidence of extrapyramidal side effects may be attributed to some property of these compounds other than their ability to act as dopamine antagonists. In fact, And6n and Stock (8) have suggested that the ability of clozapine to block muscarinic receptors is responsible for its low incidence of extrapyramidal side effects. Another discrepancy between our enzymological results and the results of studies in vivo is the relatively low potency of Fig. 4 ) in which the concentration of dopamine was held constant, and the concentration of the test substance was varied. The Ki value (19) was calculated from the relationship I50 = Ki(1 + S/Km), where L50 is the concentration of drug required to give 50% inhibition of the dopamine-stimulated increase in enzyme activity, and S is the concentration (40 MuM) of dopamine. The mean value for Km found in this series of experiments was 5 ,uM. enzyme activity, and the high potency of these compounds in haloperidol and pimozide as inhibitors of dopamine-stimulated vivo (16, 17) . However, the low aqueous solubility of these Amantadine and d,l-amphetamine, two substances believed to achieve their clinical actions in part by affecting the release and reuptake of dopamine at presynaptic dopaminergic nerve terminals, were studied for possible effects on adenylate cyclase activity in homogenates of the rat caudate nucleus. Neither compound, in concentrations up to 1000 ,iM, affected enzyme activity, either in the absence or presence of 40 1M dopamine.
Adenylate cyclase activity that could be stimulated by dopamine was also found in the olfactory tubercle of the guinea pig, golden hamster, and mouse (data not shown), as well as in the caudate nucleus from each of several mammalian species examined, including man (Table 3) . Moreover, under experimental conditions the same as those of Table 2B , the adenylate cyclase activity of the enzyme from human caudate nucleus was inhibited, in decreasing order of potency, by fluphenazine (Ki = 0.033 jM), thioridazine (Ki = 0.11 ,uM), chlorpromazine (Ki = 0.44 ,uM), and pimozide (Ki = 1.11 /aM).
DISCUSSION
The evidence presented here that dopamine-sensitive adenylate cyclase activity occurs in the olfactory tubercle, nucleus accumbens, and caudate nucleus of mammalian brain, that antipsychotic drugs are highly potent antagonists of this enzyme, and that clinically inactive compounds structurally related to the psychoactive phenothiazines are relatively weak antagonists of this enzyme, are compatible with several ideas: (a) that the dopamine receptor in these regions of the brain may be intimately associated with a dopamine-sensitive adenylate cyclase; (b) that the physiological effects of dopamine in these regions may be mediated through cyclic AMP; (c) that the extrapyramidal side effects of the antipsychotic drugs may be related to their ability to block the stimulation by dopamine of adenylate cyclase activity in the caudate nucleus; and (d) that the therapeutic effects of the antipsychotic drugs may be related to a similar action on a dopamine-sensitive adenylate cyclase in the limbic system (although dopamine-sensitive adenylate cyclase in another region could, conceivably, be the site of the therapeutic action of these drugs).
It has been suggested (18) that the endocrinological side effects of the antipsychotic drugs may result from a blockade of dopamine receptors in the median eminence, another region of the brain known to receive dopaminergic innervation. On the basis of our experiments, one might predict that dopaminesensitive adenylate cyclase also occurs in those other regions of the brain receiving dopaminergic innervation, and that the antipsychotic drugs will function in those regions, as in the caudate nucleus, the olfactory tubercle, and the nucleus accumbens, by antagonizing dopamine stimulation of adenylate cyclase activity.
